@article {235407,
	title = {Anti-HCV, nucleotide inhibitors, repurposing against COVID-19},
	journal = {Life Sciences},
	volume = {248},
	year = {2020},
	note = {<p>Export Date: 24 May 2024; Cited By: 549</p>
},
	month = {2020},
	abstract = {<p>Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today \&gt;2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for \&gt;8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). Materials and methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. Key findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection. {\textcopyright} 2020 Elsevier Inc.</p>
},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080998230\&doi=10.1016\%2fj.lfs.2020.117477\&partnerID=40\&md5=05ce39491b2be7c5eaf0502aa2add368},
	author = {Elfiky, A.A.}
}
